Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

Edwards, J. G.; Abrams, K. R.; Leverment, J. N.; Spyt, T. J.; Waller, D. A.; O'Byrne, K. J.
September 2000
Thorax;Sep2000, p731
Academic Journal
No abstract available.


Related Articles

  • Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Meniawy, T M; Creaney, J; Lake, R A; Nowak, A K // British Journal of Cancer;10/1/2013, Vol. 109 Issue 7, p1813 

    Background:Recent studies proposed neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in malignant pleural mesothelioma (MPM). We examined baseline prognostic variables including NLR and the EORTC and CALGB models as predictors of overall survival (OS) in MPM.Methods:In this...

  • Angiogenesis is an independent prognostic factor in malignant mesothelioma. Edwards, J G; Cox, G; Andi, A; Jones, J L; Walker, R A; Waller, D A; O’Byrne, K J // British Journal of Cancer;9/15/2001, Vol. 85 Issue 6, p863 

    Angiogenesis is essential for tumour growth beyond 1 to 2 mm in diameter. The clinical relevance of angiogenesis, as assessed by microvessel density (MVD), is unclear in malignant mesothelioma (MM). Immunohistochemistry was performed on 104 archival, paraffin-embedded, surgically resected MM...

  • A new prognostic score for survival of patients with chronic myeloid leukemia treated with... Hasford, Joerg; Pfirrmann, Markus; Hehlmann, Rüdiger; Allan, Norman C.; Baccarani, Michele; Kluin-Nelemans, Johanna C.; Alimena, Guiliana; Steegmann, Juan Luis; Ansari, Hassan // JNCI: Journal of the National Cancer Institute;06/03/98, Vol. 90 Issue 11, p850 

    Focuses on the development of the prognostic scoring system, which estimates survival of patients with chronic myeloid leukemia (CML), referencing to treatment with interferon alfa. How the interferon alfa is used; What the prognostic factors served as; Validation of findings.

  • Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Smits, A.; Westerberg, E.; Ribom, D. // European Journal of Nuclear Medicine & Molecular Imaging;Jan2008, Vol. 35 Issue 1, p65 

    The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC)...

  • Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma Opitz, Isabelle; Kestenholz, Peter; Lardinois, Didier; Müller, Michael; Rousson, Valentin; Schneiter, Didier; Stahel, Rolf; Weder, Walter // European Journal of Cardio-Thoracic Surgery;Apr2006, Vol. 29 Issue 4, p579 

    Abstract: Objective: To investigate the incidence and management of postoperative complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Methods: Patients with histologically proven mesothelioma of clinical stages T1–3,...

  • Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies Oosterveld, Margriet; Suciu, Stefan; Muus, Petra; Germing, Ulrich; Delforge, Michel; Belhabri, Amin; Aul, Carlo; Selleslag, Dominik; Ferrant, Augustin; Marie, Jean-Pierre; Amadori, Sergio; Jehn, Ulrich; Mandelli, Franco; Hess, Uwe; Hellström-Lindberg, Eva; Cakmak-Wollgast, Songuel; Vignetti, Marco; Labar, Boris; Willemze, Roel; Witte, Theo // Annals of Hematology;Jan2015, Vol. 94 Issue 1, p23 

    High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related factors. The purpose of this analysis is to identify...

  • Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Ghanim, B; Klikovits, T; Hoda, M A; Lang, G; Szirtes, I; Setinek, U; Rozsas, A; Renyi-Vamos, F; Laszlo, V; Grusch, M; Filipits, M; Scheed, A; Jakopovic, M; Samarzija, M; Brcic, L; Stancic-Rokotov, D; Kern, I; Rozman, A; Dekan, G; Klepetko, W // British Journal of Cancer;3/3/2015, Vol. 112 Issue 5, p783 

    Background:Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic relevance of Ki67 was studied in MPM.Methods:Ki67 index was determined in a test cohort of 187 cases from three centres. The percentage of Ki67-positive tumour cells was...

  • Malignant Pleural Mesothelioma. Neumann, Volker; Löseke, Stefan; Nowak, Dennis; Herth, Felix J. F.; Tannapfel, Andrea // Deutsches Aerzteblatt International;5/2/2013, Vol. 110 Issue 18, p319 

    Background: The incidence of malignant mesothelioma in Germany is about 20 cases per million persons per year. Its association with asbestos exposure, usually occupational, has been unequivocally demonstrated. Even though the industrial use of asbestos was forbidden many years ago, new cases of...

  • Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Linton, A; Pavlakis, N; O'Connell, R; Soeberg, M; Kao, S; Clarke, S; Vardy, J; van Zandwijk, N // British Journal of Cancer;10/28/2014, Vol. 111 Issue 9, p1860 

    Background:Although the prognosis of most patients presenting with malignant pleural mesothelioma (MPM) is poor, a small proportion survives long term. We investigated factors associated with survival in a large patient series.Methods:All patients registered with the NSW Dust Diseases Board...

  • Response to comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. Meniawy, T M; Creaney, J; Lake, R A; Nowak, A K // British Journal of Cancer;12/9/2014, Vol. 111 Issue 12, p2377 

    A response from the author of the article "Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'" in the 2014 issue is presented.


Read the Article


Sign out of this library

Other Topics